Volume 11 Supplement 1

Approaching complexities in health and environment

Review
Open Access

Bladder cancer, a review of the environmental risk factors

  • Silvia Letašiová1Email author,
  • Alžbeta Medveďová1,
  • Andrea Šovčíková1,
  • Mária Dušinská2, 4,
  • Katarína Volkovová2,
  • Claudia Mosoiu3 and
  • Alena Bartonová4
Environmental Health201211(Suppl 1):S11

https://doi.org/10.1186/1476-069X-11-S1-S11

©  Letašiová et al; licensee BioMed Central Ltd. 2012

Published: 28 June 2012

Abstract

Background

Many epidemiological studies and reviews have been performed to identify the causes of bladder cancer. The aim of this review is to investigate the links between various environmental risk factors and cancer of the bladder.

Methods

A systematic literature search was performed using PubMed, Science Direct, Scopus, Scholar Google and Russian Google databases to identify reviews and epidemiological studies on bladder cancer risk factors associated with the environment published between 1998 and 2010. Only literature discussing human studies was considered.

Results

Smoking, mainly cigarette smoking, is a well known risk factor for various diseases, including bladder cancer. Another factor strongly associated with bladder cancer is exposure to arsenic in drinking water at concentrations higher than 300 µg/l. The most notable risk factor for development of bladder cancer is occupational exposure to aromatic amines (2-naphthylamine, 4-aminobiphenyl and benzidine) and 4,4'-methylenebis(2-chloroaniline), which can be found in the products of the chemical, dye and rubber industries as well as in hair dyes, paints, fungicides, cigarette smoke, plastics, metals and motor vehicle exhaust. There are also data suggesting an effect from of other types of smoking besides cigarettes (cigar, pipe, Egyptian waterpipe, smokeless tobacco and environmental tobacco smoking), and other sources of arsenic exposure such as air, food, occupational hazards, and tobacco. Other studies show that hairdressers and barbers with occupational exposure to hair dyes experience enhanced risk of bladder cancer. For example, a study related to personal use of hair dyes demonstrates an elevated bladder cancer risk for people who used permanent hair dyes at least once a month, for one year or longer.

Conclusion

Smoking, in particular from cigarettes, exposure to arsenic in drinking water, and occupational exposure to aromatic amines and 4,4'-methylenebis(2-chloroaniline) are well known risk factors for various diseases including bladder cancer. Although the number of chemicals related to occupational exposure is still growing, it is worth noting that it may take several years or decades between exposure and the subsequent cancer.

Background

Bladder cancer is the 10th most common cancer worldwide, with the highest rates reported in Europe, North America and Australia, and accounting for an estimated 261 000 new cases diagnosed and 115 000 deaths each year; by comparison, relatively low rates are found in the Far Eastern countries [1, 2]. In Europe, bladder cancer is the 5th most commonly diagnosed cancer type and the 9th leading cause of cancer mortality [2]. It affects men more frequently than women [3]. Typical of solid tumours, bladder cancer incidence increases with age. Tumours of the bladder rarely occur before the age of 40 – 50, arising most commonly in the seventh decade of life [4, 5]. The median ages at diagnosis are 69 years for men and 71 for women [6].

Histologically, most cases of bladder cancer are transitional cell carcinomas (90 %); 70 % of these are superficial and papillary subtypes [7]. The less common types are squamous cell carcinoma (3 - 5 %); adenocarcinoma (0.5 to 2 %); small cell carcinoma (less than 0.5 %); and sarcoma, carcinosarcoma/sarcomatoid tumours, paraganglioma, melanoma and lymphoma (less than 0.1 %) [8]. Haematuria, i.e., frequent urination and pain during urination, are the most common symptoms of bladder cancer [4].

The aim of this review is to investigate the links between environmental risk factors and bladder cancer. Examples include the effect of different types of smoking (cigarette, cigar, pipe and environmental tobacco smoking); the effect of arsenic in drinking water, air, food, occupational hazards, and tobacco; and the effect of occupational exposure to aromatic amines (2-naphthylamine, 4-aminobiphenyl and benzidine) and 4,4'-methylenebis(2-chloroaniline) that can be found in chemical, dye and rubber industries as well as in hair dyes, paints, fungicides, cigarette smoke, plastics, metal and motor vehicle exhaust in relation to bladder cancer.

Methods

A systematic literature search was performed using PubMed, Science Direct, Scopus, Scholar Google and Russian Google databases to identify reviews and epidemiological studies on bladder cancer risk factors associated with the environment published between 1998 and 2010. Only literature discussing human studies was considered.

Results

Smoking

Smoking is a well known risk factor of chronic lung disease, heart disease and various types of cancer including bladder cancer [9, 10]. Several epidemiological studies and reviews describe the impact of cigarette, cigar, pipe and environmental tobacco smoking.

Cigarette smoking is the primary risk factor for bladder cancer [3, 6, 11]. In a recent meta-analysis of 43 published case-control and cohort studies, Zeegers et al. [12] concluded that current cigarette smokers have an approximately threefold higher risk of bladder cancer than non-smokers. In a combined analysis of 11 case-control studies from six European countries, risk for bladder cancer increased with duration of smoking (number of years smoked) and intensity of smoking (number of cigarettes smoked per day) [3, 13, 14]. The age- and gender-adjusted summary odds ratios for current and former cigarette smokers compared with those for non-smokers were 3.33 (95 % confidence interval (CI), 2.63 – 4.21) and 1.98 (95 % CI 1.72 – 2.29), respectively [4]. The Netherlands Cohort Study the associations between cigarette smoking and bladder cancer risks were studied in detail [15]. Zeegers et al. [15] found out that the tar and nicotine content of cigarettes, and filter-tip usage were only weakly associated with bladder cancer risk. Cancer of the urinary bladder has a relative risk associated with tobacco use of 3.0; the relative risk for pancreas cancer associated with tobacco use is 2.0 – 4.0 [11].

Given convincing evidence for a substantially increased risk of bladder cancer for cigarette smokers, Zeegers et al. [4] calculated the etiologic fraction of cigarette smoking which accounts for 23 % of all female bladder cancer, whereas in men 50 % of the cancer is attributed to cigarette smoking.

Risk depends on the method of tobacco smoking: pure cigarette smokers were at higher risk (95 % CI 2.9 – 4.2) than pure pipe smokers (95 % CI 1.2 – 3.1) or pure cigar smokers (95 % CI 1.6 – 3.5) [16]. The effect of cigar smoking may be limited to people who inhale [17]. Furthermore, Iscovich et al. [18] suggested that users of black tobacco have a two to three times higher risk than users of Virginia tobacco. In the Netherlands Cohort Study, Zeegers et al. [4] confirmed a substantially increased risk of bladder cancer for current cigar (95 % 1.68 – 4.93) and pipe smokers (95 % 1.67 – 5.50) versus those who have never smoked tobacco. However, the evidence of an association between bladder cancer risk and Egyptian waterpipe and smokeless tobacco use is rarely reported [3].

The precise mechanism by which cigarette, cigar and pipe smoking causes bladder cancer has yet to be determined. Zeegers et al. [4] assumed that the risk of bladder cancer is related to some of the large number of chemicals present in smoke, such as 2-naphthylamine and 4-aminobiphenyl, leading candidates for the specific etiologic agents. On the other hand, cigar and pipe smokers inhale less than cigarette smokers, which can explain an increased cancer incidence for cigar and pipe smokers in local areas of the human body (such as head cancer, neck cancer) and no increased risk through a systemic effect (such as bladder cancer) [4].

The relationship of environmental tobacco smoking has been investigated only in a few studies [4, 19, 20]. Kabat et al. [21] reported data from a population-based US case control study where no significant risk of bladder cancer in either sex was seen when comparing 84 non-smoking cases and 266 hospital controls [19]. In a large Japanese prospective study no significant increased risk was observed in the wife associated with the husband's smoking [22]. A population-based case-control study was conducted in Canada [23]. Risk of bladder cancer was not increased in relation to environmental tobacco smoking exposure at home or at work [19].

There is good evidence that stopping smoking reduces the rate of recurrence for many cancers [24]. For bladder cancer, Aveyard et al. [25] examined 15 studies that showed evidence that continued smoking or a lifetime of smoking constitutes a moderate risk factor for recurrence and death, and that stopping smoking could favourably change this. However, the evidence base for this is weak because of the methodological shortcomings and because most results of the studies were not statistically significant [25].

Arsenic in drinking water

Arsenic, a naturally occurring metalloid found in air, soil and water, exists in both organic and inorganic states. Whereas organic forms are considered non toxic, inorganic forms are toxic [26]. In countries such as Bangladesh, China, Hungary, and India, among others, arsenic is found at high concentration in ground water and surface soil [27].

There is strong evidence for a link between bladder cancer and exposure to arsenic (As) in drinking water at concentrations exceeding 300 – 500 µg/l [1, 28]; however, there seems to be no elevated risk with As concentrations below 200 µg/l [29], except for the smokers [30]. On the other hand, Meliker and Nriagu [1] reported that health risks from As exposure in the 10 – 100 µg/l range are not obvious. Given low-to-moderate concentrations of As in drinking water, other sources of As exposure such as air, food, occupational hazards, and tobacco may be important [1, 28, 30]. Exposure to other potential bladder carcinogens in drinking water, such as disinfection byproducts or nitrates, along with mediating factors in the diet, such as selenium and zinc, may also prove to be decisive factors [1]. On the other hand, Kurttio et al. [31] reported in a Finnish study that in spite of very low As exposure levels (0.5 µg/l) they found evidence of a link between As and bladder cancer risk and provided evidence for synergistic effects of smoking and nutritional factors with As.

The mechanism of arsenic-induced bladder cancer remains unclear. Arsenic inhibits indirectly sulfhydryl containing enzymes and interferes with cellular metabolism such as cytotoxicity, genotoxicity and inhibition of enzymes with antioxidant function [32]. On the other hand, the p53 protein may be involved in the development of bladder cancer. In a Taiwanese study, bladder tumours from people chronically exposed to As showed mutations in the p53 gene at codon 175 and transitions at points 9 and 10 [30]. However, in a South American study, Moore et al. [33] did not find evidence that As exposure was associated with an increased prevalence of p53 mutations or immunopositivity of p53 protein in bladder cancer.

There is also evidence that the process of arsenic carcinogenesis may be modulated by genetic differences in DNA repair [34]. Andrew et al (2009) [34] observed gene-environment interaction of 549 controls and 342 cases with arsenic exposure in relation to bladder cancer risk for a variant allele of the double-strand break repair gene XRCC3 T241M (odds ratios (OR) adjusted for age, gender, smoking status (former and current): OR 2.8 (1.1 – 7.3)).

Occupational exposure

Aromatic amines

The most notable risk factor for the development of bladder cancers is occupational exposure to aromatic amines, first noted in England over 100 years ago. The compounds 2-naphthylamine, 4-aminobiphenyl and benzidine can be found in the products from the chemical, dye and rubber industries as well as in hair dyes, paints, fungicides, cigarette smoke, plastics, metal and motor vehicle exhaust and pollutant emissions from industrial installations [35–38].

In 1954, Case et al. [39] reported a 200-fold increased bladder cancer risk for English and Welsh workers exposed to 2-naphthylamine. In the cohort study performed on more than 11 000 workers in the rubber industry, elevated standardised mortality ratios (SMR) for bladder cancer were observed for “storage and shipment” (SMR 253; 95 % CI 93-551) and for “general work” in this industry (SMR 159; 95 % CI 92-279) [40].

4-aminobiphenyl, carcinogenic aromatic amine, present as a carcinogenic component of tobacco smoke is also used in the rubber industry. In a study involving 171 workers in the rubber industry, 19 cases of bladder cancer were observed [40].

Benzidine, used in dye production and the rubber industry, has been identified as the most important carcinogenic aromatic amine regarding human bladder damage. 92 of 331 workers of one of the most important industrial facilities in Leverkusen, Germany, who had been exposed to benzidine production before 1967, eventually contracted bladder cancer [40]. In a Chinese cohort study, where 784 workers were exposed to benzidine, a 35-fold increased of bladder cancer risk was observed [41].

Individuals with occupational exposure to hair dyes such as hairdressers and barbers experience enhanced risk of bladder cancer although it is unclear if other lifestyle aspects are responsible for the increase in bladder cancer risk [36]. In a large population-based case-control study in Los Angeles, personal use of hair dyes was assessed according to the types of hair dyes normally used and compared with people who did not use hair dyes [42]. An elevated bladder cancer risk (odds ratio (OR) 1.9; 95 % CI 1.1 -3.3) was claimed for those who used permanent hair dyes at least once a month, for 1 year or longer. The risk increased to 3.3 (95 % CI 1.3 – 8.4) for those who used permanent hair dyes at least once a month for 15 and more years. Hairdressers who performed their jobs for more than 10 years showed a 5-fold increased risk (95 % CI 1.3 – 19.2) [40].

Firefighters exposed to a long list of carcinogens in combustion products including asbestos, polycyclic aromatic hydrocarbons, benzene, lead and aromatic amines have been shown to be at increased risk of developing a number of cancers including multiple myeloma, non-Hodgkin’s lymphoma, prostate cancer, testicular cancer leukemia, skin cancer, malignant melanoma, brain cancer, and cancer of the rectum, colon, stomach, buccal cavity and pharynx [43].

4,4'-methylenebis(2-chloroaniline) (MBOCA)

4,4'-methylenebis(2-chloroaniline) (MBOCA) is a synthetic chemical widely used in industry primarily to produce castable polyurethane parts. Most exposure to MBOCA occurs in the workplace; the workers may inhale small particles of MBOCA in the air or absorb MBOCA dust or vapor through the skin [37]. In a Taiwanese study, a total of 70 MBOCA-exposed workers and 92 non-exposed workers were screened for bladder cancer. The study identified a proven bladder carcinoma in MBOCA-manufacturing factories; a worker with suspected malignant cells; and a worker with atypical cytology combined with gross hematuria. The findings of this study support the conclusions from other studies that MBOCA is potentially carcinogenic to humans and control measures (such as issuing work clothing that must not be worn at home; requiring to shower at the end of the work shift; and improving the ventilation system) are needed to prevent overexposure from inhalation and skin absorption [37].

It has been estimated that the occupational exposures are responsible for 18 % of bladder cancer cases. 2 years' exposure may be sufficient to increase this risk, but the time between exposure and subsequent cancer may be several decades [37].

Conclusion

In this review, we investigated the associations of the environmental risk factors with bladder cancer. Smoking, in particular cigarette smoking, is a well known risk factor for various diseases including bladder cancer. The effects of other type of smoking (cigar, pipe, Egyptian waterpipe, smokeless tobacco and environmental tobacco smoking) have been investigated only in a few studies. The precise mechanism of smoking-induced bladder cancer has yet to be determined. Another factor strongly associated with bladder cancer is exposure to arsenic in drinking water at concentrations higher than 300 µg/l. Other sources of arsenic exposure such as air, food, occupational hazards, and tobacco may be important, but there are not enough studies to allow demonstration of a link. The mechanism of arsenic-induced bladder cancer remains unclear. The most notable risk factor for the development of bladder cancers is occupational exposure to aromatic amines (2-naphthylamine, 4-aminobiphenyl and benzidine) and 4,4'-methylenebis(2-chloroaniline) that can be found in the chemical, dye and rubber industries as well as in hair dyes, paints, fungicides, cigarette smoke, plastics, metal and motor vehicle exhaust. Although the number of chemicals related to occupational exposure is still growing, it is worth noting that it may take several years or decades between exposure and the subsequent cancer.

Declarations

Acknowledgements

The authors would like to thank William A. Lahoz (NILU) for the English language review.

The work has been funded by the EU FP6 coordination action HENVINET, contract no 037019.

This article has been published as part of Environmental Health Volume 11 Supplement 1, 2012: Approaching complexities in health and environment. The full contents of the supplement are available online at http://www.ehjournal.net/supplements/11/S1.

Authors’ Affiliations

(1)
Institute of Biochemistry, Nutrition and Health Protection, Faculty of Chemical and Food Technology, Slovak University of Technology
(2)
Research Base of Slovak Medical University
(3)
Institute of Food Bioresources
(4)
NILU-Norwegian Institute for Air Research

References

  1. Meliker JR, Nriagu JO: Arsenic in drinking water and bladder cancer: review of epidemiological evidence. Trace Metals and other Contaminants in the Environment. 2007, 9: 551-584.View ArticleGoogle Scholar
  2. Larsson SC, Andersson SO, Johansson JE, Wolk A: Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer. 2008, 44 (17): 2655-2660. 10.1016/j.ejca.2008.07.012.View ArticleGoogle Scholar
  3. Kuper H, Boffetta P, Adami HO: Tobacco use and cancer causation: association by tumour type. J Internal Medicine. 2002, 252: 206-224. 10.1046/j.1365-2796.2002.01022.x.View ArticleGoogle Scholar
  4. Zeegers MPA, Kellen E, Buntinx F, van den Brandt PA: The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 2004, 21: 392-401. 10.1007/s00345-003-0382-8.View ArticleGoogle Scholar
  5. Shariat SF, Milowsky M, Droller MJ: Bladder Cancer in Elderly. Urol Oncopl. 2009, 27: 653-667. 10.1016/j.urolonc.2009.07.020.View ArticleGoogle Scholar
  6. Volanis D, Kadiyska T, Galanis A, Delakas D, Logotheti S, Zoumpourlis V: Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicology Letters. 2010, 193: 131-137. 10.1016/j.toxlet.2009.12.018.View ArticleGoogle Scholar
  7. Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD: Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer. Cancer Genet Cytogenet. 2008, 184: 1-8. 10.1016/j.cancergencyto.2008.02.015.View ArticleGoogle Scholar
  8. Dahm P, Gschwend JE: Malignant Non-Urothelial Neoplasms of the Urinary Bladder: A Review. Eur Urol. 2003, 44: 672-681. 10.1016/S0302-2838(03)00416-0.View ArticleGoogle Scholar
  9. Doll R, Peto R, Wheatley K, Gray R, Sutherland I: Mortality in relation to smoking. 40 years'observations on male British doctors. Br Med J. 1994, 309: 901-911. 10.1136/bmj.309.6959.901.View ArticleGoogle Scholar
  10. Weires M, Bermejo JL, Sundquist J, Hemminki K: Clustering of concordant and discordant cancer types in Swedish couples is rare. Eur J Cancer.Google Scholar
  11. Stewart SL, Cardinez CJ, Richardson LC, Norman L, Kaufmann R, Pechacek TF, Thompson TD, Weir HK, Sabatino SA: Surveillance for cancers associated with tobacco use--United States, 1999-2004. MMWR Surveill. Summ. 2008, 57: 1-33.Google Scholar
  12. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA: The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiological studies. Cancer. 2000, 89: 630-639. 10.1002/1097-0142(20000801)89:3<630::AID-CNCR19>3.0.CO;2-Q.View ArticleGoogle Scholar
  13. Brennan P, Bogillot O, Cordier S, Greise E, Schill W, Vineis P, Lopez-Abente G, Tzonou A, Chang-Claude J, Bolm-Audorff U, Jöckel KH, Donato F, Serra C, Wahrendorf J, Hours M, T'Mannetje A, Kogevinas M, Boffeta P: Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer. 2000, 86: 289-94. 10.1002/(SICI)1097-0215(20000415)86:2<289::AID-IJC21>3.0.CO;2-M.View ArticleGoogle Scholar
  14. Brennan P, Bogillot O, Greiser E, Chang-Claude J, Wahrendorf J, Cordier S, Jöckel KH, Lopez-Abente G, Tzonou A, Vineis P, Donato F, Hours M, Serra C, Bolm-Audorff U, Schill W, Kogevinas M, Boffeta P: The contribution of cigarette smoking to bladder cancer risk in women (pooled European data). Cancer Causes Control. 2001, 12: 411-417. 10.1023/A:1011214222810.View ArticleGoogle Scholar
  15. Zeegers MP, Goldbohm RA, van den Brandt PA: A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). Cancer Causes Control. 2002, 13: 83-90. 10.1023/A:1013954932343.View ArticleGoogle Scholar
  16. Pitard A, Brennan P, Clavel J, Greiser E, Lopez-Abente G, Chang-Claude J, Wahrendorf J, Serra C, Kogevinas M, Boffeta P: Cigar, pipe, and cigarette smoking and bladder cancer risk in European men. Cancer Causes Control. 2001, 12: 551-556. 10.1023/A:1011291015233.View ArticleGoogle Scholar
  17. Shapiro JA, Jacobs EJ, Thun MJ: Cigar smoking in men and risk of death from tobacco-related cancer. J Natl Cancer Inst. 2000, 92: 333-337. 10.1093/jnci/92.4.333.View ArticleGoogle Scholar
  18. Iscovich J, Castelletto R, Esteve J, Munoz N, Colanzi R, Coronel A, Deamezola I, Tassi V, Arslan A: Tobacco smoking, occupational exposure and bladder cancer in Argentina. Int J Cancer. 1987, 40: 734-740. 10.1002/ijc.2910400604.View ArticleGoogle Scholar
  19. Lee PN: Environmental tobacco smoke and cancer of sites other than the lung in adult non- smokers. Food Chem Toxicol. 2002, 40: 747-766. 10.1016/S0278-6915(02)00027-3.View ArticleGoogle Scholar
  20. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 89, Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines. 2007, 227-Google Scholar
  21. Kabat GC, Dieck GS, Wynder EL: Bladder cancer in nonsmokers. Cancer. 1986, 57: 362-367. 10.1002/1097-0142(19860115)57:2<362::AID-CNCR2820570229>3.0.CO;2-F.View ArticleGoogle Scholar
  22. Hirayama T: Passive smoking and cancer: an epidemiological review. GANN Monograph on Cancer Research. 1987, 33: 127-135.Google Scholar
  23. Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R, Miller AB: Risk of bladder cancer by source and type of exposure: a case control study. Int J Cancer. 1989, 44: 622-628. 10.1002/ijc.2910440411.View ArticleGoogle Scholar
  24. Richardson GE, Tucker MA, Venzon DJ, Linnoila RI, Phelps R, Phares JC: Smoking cessation after successful ttreatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med. 1993, 119: 383-390.View ArticleGoogle Scholar
  25. Aveyard P, Adab P, Cheng KK, Wallace DMA, Hey K, Murphy MFG: Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int. 2002, 90: 228-239. 10.1046/j.1464-410X.2002.02880.x.View ArticleGoogle Scholar
  26. Gbaruko BC, Ana GREE, Nwachukwu : Ecotoxicology of arsenic in the hydrosphere: Implications for public health. African Journal of Biotechnology. 2008, 7 (25): 4737-4742.Google Scholar
  27. Peralta-Videa JR, Lopez ML, Narayan M, Saupe G, Gardea-Torresdey : The biochemistry of environmental heavy metal uptake by plants: Implications for the food chain. The International Journal of Biochemistry & Cell Biology. 2009, 41: 1665-1677. 10.1016/j.biocel.2009.03.005.View ArticleGoogle Scholar
  28. Navarro Silvera SA, Rohan TE: Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control. 2007, 18: 7-27. 10.1007/s10552-006-0057-z.View ArticleGoogle Scholar
  29. Mink PJ, Alexander DD, Barraj LM, Kelsch MA, Tsuji JS: Low-level arsenic exposure in drinking water and bladder cancer: A review. Regulatory Toxicology and Pharmacology. 2008, 52: 299-310. 10.1016/j.yrtph.2008.08.010.View ArticleGoogle Scholar
  30. Tapio S, Grosche B: Arsenic in the aetiology of cancer. Review. Mutation Research. 2006, 612: 215-146. 10.1016/j.mrrev.2006.02.001.View ArticleGoogle Scholar
  31. Kurttio P, Pukkala E, Kahelin H, Auvinen A, Pekkanen J: Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ Health Perspect. 1999, 107: 705-710. 10.1289/ehp.99107705.View ArticleGoogle Scholar
  32. Anetor JI, Wanibuchi H, Fukushima S: Arsenic exposure and its health effects and risk of cancer in developing countries: micronutrients as host defence. Asian Pac J Cancer Prev. 2007, 8: 13-23.Google Scholar
  33. Moore LE, Smith AH, Eng C, DeVries S, Kalman V, Bhargava V, Chew K, Ferreccio C, Rey OA, Hopenhayn C, Biggs ML, Bates MN, Waldman FM: P53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis. 2003, 24: 1785-1791. 10.1093/carcin/bgg136.View ArticleGoogle Scholar
  34. Andrew AS, Mason RA, Kelsey KT, Schned AR, Marsit CJ, Nelson HH, Karagas MR: DNA repair genotype interacts with arsenic exposure to increase bladder cancer risk. Toxicology Letters. 2009, 187: 10-14. 10.1016/j.toxlet.2009.01.013.View ArticleGoogle Scholar
  35. Snyderwine EG, Sinha R, Felton J, Ferguson LR: Highlights of the Eight International Conference on Carcinogenic/Mutagenic N-Substituted Aryl Compounds. Mutat Res. 2002, 506-507: 1-8.View ArticleGoogle Scholar
  36. Yu MC, Skipper PL, Tannenbaum SR, Chan KK, Ross RK: Arylamine exposures and bladder cancer risk. Mutat Res. 2002, 506-507: 21-28.View ArticleGoogle Scholar
  37. Chen HI, Liou SH, Loh CH, Uang SN, Yu YC, Shih TS: Bladder cancer screening and monitoring of 4,4'-methylenebis(2-chloroaniline) exposure among workers in Taiwan. Urology. 2005, 66: 305-310. 10.1016/j.urology.2005.02.031.View ArticleGoogle Scholar
  38. Garcia-Pérez J, Pollán M, Boldo E, Pérez-Gómez B, Aragonés N, Lope V, Ramis R, Vidal E, López-Abente G: Mortality due to lung, laryngeal and bladder cancer in towns lying in the vicinity of combustion installations. Science of the Total Environment. 2009, 407: 2593-2602. 10.1016/j.scitotenv.2008.12.062.View ArticleGoogle Scholar
  39. Case RAM, Hosker ME: Tumours of the urinary bladder as an occupational disease in the rubber industry in England and Wales. Br J Prev Soc Med. 1954, 8: 39-50.Google Scholar
  40. Golka K, Wiese A, Assennato G, Bolt H: Occupational exposure and urological cancer. World J Urol. 2004, 21: 382-391. 10.1007/s00345-003-0377-5.View ArticleGoogle Scholar
  41. Ma QW, Lin GF, Qin YQ, Lu DR, Golka K, Geller F, Chen JG, Shen JH: GSTP1 A1578G(Ile105Val) polymorphism in benzidine-exposed workers: an association with cytological grading of exfoliated urothelial cells. Pharmacogenetics. 2003, 13: 409-415. 10.1097/00008571-200307000-00006.View ArticleGoogle Scholar
  42. Gago-Dominguez M, Castelao JE, Yuan JM, Yu MC, Ross RK: Use of permanent hair dyes and bladder-cancer risk. Int J Cancer. 2001, 91: 575-579. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1092>3.0.CO;2-S.View ArticleGoogle Scholar
  43. Milham S: Most cancer in firefighters is due to radio-frequency radiation exposure not inhaled carcinogens. Medical Hypotheses. 2009, 73: 788-789. 10.1016/j.mehy.2009.04.020.View ArticleGoogle Scholar

Copyright

© Letašiová et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement